Literature DB >> 12379632

Bone destruction in arthritis.

E M Gravallese1.   

Abstract

Rheumatoid arthritis (RA) is characterised by the presence of an inflammatory synovitis accompanied by destruction of joint cartilage and bone. Destruction of cartilage matrix results predominantly from the action of connective tissue proteinases released by RA synovial tissues, chondrocytes, and pannus tissue. Several lines of evidence in RA and in animal models of arthritis support a role for osteoclasts in the pathogenesis of bone erosions. RA synovial tissues produce a variety of cytokines and growth factors that may increase osteoclast formation, activity, and/or survival. These include interleukin 1alpha (IL1alpha) and beta, tumour necrosis factor alpha (TNFalpha), IL11, IL17, and macrophage colony stimulating factor (M-CSF). Receptor activator of NFkappaB ligand (RANKL) is an essential factor for osteoclast differentiation and also functions to augment T cell-dendritic cell cooperative interactions. CD4+ T cells and synovial fibroblasts derived from RA synovium are sources of RANKL. Furthermore, in collagen induced arthritis (CIA), blockade with osteoprotegerin (OPG), a decoy receptor for RANKL, results in protection from bone destruction. To further evaluate the role of osteoclasts in focal bone erosion in arthritis, arthritis was generated in the RANKL knockout mouse using a serum transfer model. Despite ongoing inflammation, the degree of bone erosion in arthritic RANKL knockout mice, as assessed by microcomputed tomography and correlated histopathological analysis, was dramatically reduced compared with that seen in arthritic control mice. Cartilage damage was present in both the arthritic RANKL knockout mice and in arthritic control littermates, with a trend toward milder cartilage damage in the RANKL knockout mice. This study supports the hypothesis that osteoclasts play an important part in the pathogenesis of focal bone erosion in arthritis, and reveals distinct mechanisms of cartilage destruction and bone erosion in this animal model of arthritis. Future directions for research in this area include the further investigation of a possible direct role for the RANKL/RANK/OPG system in cartilage metabolism, and the possible role of other cell types and cytokines in bone erosion in arthritis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379632      PMCID: PMC1766721          DOI: 10.1136/ard.61.suppl_2.ii84

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  45 in total

1.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Authors:  D L Lacey; H L Tan; J Lu; S Kaufman; G Van; W Qiu; A Rattan; S Scully; F Fletcher; T Juan; M Kelley; T L Burgess; W J Boyle; A J Polverino
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.

Authors:  S Kotake; N Udagawa; M Hakoda; M Mogi; K Yano; E Tsuda; K Takahashi; T Furuya; S Ishiyama; K J Kim; S Saito; T Nishikawa; N Takahashi; A Togari; T Tomatsu; T Suda; N Kamatani
Journal:  Arthritis Rheum       Date:  2001-05

3.  Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation.

Authors:  M Nagai; S Kyakumoto; N Sato
Journal:  Biochem Biophys Res Commun       Date:  2000-03-16       Impact factor: 3.575

4.  The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.

Authors:  F Gori; L C Hofbauer; C R Dunstan; T C Spelsberg; S Khosla; B L Riggs
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

5.  The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.

Authors:  N L Fazzalari; J S Kuliwaba; G J Atkins; M R Forwood; D M Findlay
Journal:  J Bone Miner Res       Date:  2001-06       Impact factor: 6.741

6.  Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent.

Authors:  I Itonaga; Y Fujikawa; A Sabokbar; D W Murray; N A Athanasou
Journal:  J Pathol       Date:  2000-09       Impact factor: 7.996

7.  Expression of osteoclast differentiation factor in rheumatoid arthritis.

Authors:  Y Shigeyama; T Pap; P Kunzler; B R Simmen; R E Gay; S Gay
Journal:  Arthritis Rheum       Date:  2000-11

8.  Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.

Authors:  H Takayanagi; H Iizuka; T Juji; T Nakagawa; A Yamamoto; T Miyazaki; Y Koshihara; H Oda; K Nakamura; S Tanaka
Journal:  Arthritis Rheum       Date:  2000-02

9.  Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis.

Authors:  E Romas; O Bakharevski; D K Hards; V Kartsogiannis; J M Quinn; P F Ryan; T J Martin; M T Gillespie
Journal:  Arthritis Rheum       Date:  2000-04

10.  Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Authors:  H Min; S Morony; I Sarosi; C R Dunstan; C Capparelli; S Scully; G Van; S Kaufman; P J Kostenuik; D L Lacey; W J Boyle; W S Simonet
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  105 in total

1.  Chronic Calcium Channel Inhibitor Verapamil Antagonizes TNF-α-Mediated Inflammatory Reaction and Protects Against Inflammatory Arthritis in Mice.

Authors:  Wenhan Wang; Zhong Li; Qingjuan Meng; Pei Zhang; Pengcheng Yan; Zhenbiao Zhang; Hao Zhang; Jingrui Pan; Yujia Zhai; Yaoge Liu; Xiaokai Wang; Weiwei Li; Yunpeng Zhao
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

2.  Myeloid-derived suppressor cells contribute to bone erosion in collagen-induced arthritis by differentiating to osteoclasts.

Authors:  Hui Zhang; Yuefang Huang; Shuang Wang; Rong Fu; Chaohuan Guo; Hongyue Wang; Jijun Zhao; Felicia Gaskin; Jingxian Chen; Niansheng Yang; Shu Man Fu
Journal:  J Autoimmun       Date:  2015-08-28       Impact factor: 7.094

3.  Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling.

Authors:  W He; B N Cronstein
Journal:  Purinergic Signal       Date:  2012-02-05       Impact factor: 3.765

4.  Dendritic cell responses to surface properties of clinical titanium surfaces.

Authors:  Peng Meng Kou; Zvi Schwartz; Barbara D Boyan; Julia E Babensee
Journal:  Acta Biomater       Date:  2010-10-25       Impact factor: 8.947

Review 5.  Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.

Authors:  Shi Wei; Gene P Siegal
Journal:  Pathol Res Pract       Date:  2008-08-30       Impact factor: 3.250

Review 6.  Bone health and systemic lupus erythematosus.

Authors:  Chin Lee; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

7.  M-CSF mediates TNF-induced inflammatory osteolysis.

Authors:  Hideki Kitaura; Ping Zhou; Hyun-Ju Kim; Deborah V Novack; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

Review 8.  Inhibitory CD8+ T cells in autoimmune disease.

Authors:  Masakatsu Suzuki; Christine Konya; Jörg J Goronzy; Cornelia M Weyand
Journal:  Hum Immunol       Date:  2008-09-21       Impact factor: 2.850

Review 9.  [Rheumatoid arthritis. Target outcome for treatment].

Authors:  D Aletaha; J Smolen
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

10.  Kinetics and interplay of mediators of inflammation-induced bone damage in the course of adjuvant arthritis.

Authors:  S M Nanjundaiah; J P Stains; K D Moudgil
Journal:  Int J Immunopathol Pharmacol       Date:  2013 Jan-Mar       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.